Devyser Diagnostics
Logotype for Devyser Diagnostics

Devyser Diagnostics (DVYSR) investor relations material

Devyser Diagnostics Q4 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Devyser Diagnostics
Q4 2025 earnings summary12 Feb, 2026

Executive summary

  • Achieved record Q4 2025 sales of SEK 72 million, up 20% year-over-year in local currencies, and full-year sales of SEK 250.5 million, up 15.5%, with EBIT turning positive at SEK 10.1 million compared to -SEK 62 million last year.

  • Q4 EBIT reached SEK 18 million (25% margin), and full-year EBIT margin was 4%, reflecting improved profitability from cost control and reorganization.

  • Maintained a strong cash position of SEK 77.5 million at year-end, with no debt reported in some sources.

  • Focused on profitable growth, cost discipline, innovation, and strategic investments and partnerships.

  • No dividend proposed for 2025.

Financial highlights

  • Q4 revenue: SEK 72 million, up from SEK 64 million in Q4 2024; full-year revenue up 15.5% to SEK 250.5 million (20.2% FX adjusted).

  • Gross margin for Q4 at 79.5%; full-year gross margin at 80.6%.

  • Q4 EBIT: SEK 18 million (25% margin), up from -SEK 3.7 million last year.

  • Cash flow from operations: SEK 12 million in Q4, SEK 8 million for the year.

  • Cash and cash equivalents at year-end: SEK 77.5 million.

Outlook and guidance

  • Expect continued cost discipline and potential investments in commercial organization as growth accelerates.

  • U.S. growth expected to accelerate post-MolDX reimbursement approval, with ongoing FDA program and new product launches in transplantation.

  • Focus on capitalizing on launched products, R&D for new launches in 2026, and market share gains in Italy and Spain.

  • Ongoing efforts to improve organizational efficiency and maintain positive cash flow.

  • Optimism for 2026, with focus on profitable growth, innovation, and positive cash flow.

What sustains positive operating profit?
MolDx delay impact on US market entry
Illumina deal: new customer groups?
Gross margin improvement plan for 2026
Illumina partnership: expected instrument placement
Cybergene acquisition: NGS conversion strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Devyser Diagnostics earnings date

Logotype for Devyser Diagnostics
Q1 202627 Apr, 2026
Devyser Diagnostics
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Devyser Diagnostics earnings date

Logotype for Devyser Diagnostics
Q1 202627 Apr, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Devyser Diagnostics AB is a Swedish company that develops, manufactures, and sells advanced diagnostic kits for DNA testing. Their products are primarily used in the fields of hereditary diseases, oncology, and post-transplantation monitoring. These diagnostic solutions enable laboratories to conduct complex genetic tests, including those for cancer treatments, prenatal screening, and transplant patient follow-ups. The company also provides software tools for data analysis and interpretation to support their test kits. The company is headquartered in Stockholm, Sweden, and its shares are traded on the Nasdaq Stockholm.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage